Spots Global Cancer Trial Database for BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Official Title: A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours
Study ID: NCT04421820
Study Description
Brief Summary: BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California, Los Angeles, Santa Monica, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Cross Cancer Institue, Edmonton, Alberta, Canada
Juravinski Cancer Centre, Hamilton, Ontario, Canada
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Jewish General Hospital, Montreal, Quebec, Canada
McGill University Health Centre Glen Site, Montréal, Quebec, Canada
National Cancer Center, Goyang, , Korea, Republic of
Kangbuk Samsung Hospital, Seoul, , Korea, Republic of
Samsung Medical Center, Seoul, , Korea, Republic of
Seoul National University Hospital, Seoul, , Korea, Republic of
Severance Hospital - Yonsei University, Seoul, , Korea, Republic of
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
